# argenx SE > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/argenx SE). ## Overview argenx SE is a Dutch biopharmaceutical company focused on discovering and commercializing antibody-based medicines for severe autoimmune diseases. Its business is built around immunology research, clinical development, and global commercialization of therapies, including its FcRn-blocking platform and related pipeline programs. ## Products & services • VYVGART (efgartigimod) for autoimmune diseases • VYVGART HYTRULO subcutaneous therapy • FcRn-blocking antibody platform • Immunology pipeline development • Clinical trial and translational research programs - **Commercial immunology medicines** (70%) — Approved antibody therapies sold for severe autoimmune diseases. - **Late-stage pipeline programs** (20%) — Clinical-stage immunology assets advancing toward potential approval. - **Research platform and discovery** (10%) — Internal and partnered discovery work that feeds the pipeline. - VYVGART (efgartigimod) for autoimmune diseases - VYVGART HYTRULO subcutaneous therapy - FcRn-blocking antibody platform - Immunology pipeline development - Clinical trial and translational research programs ## Customers argenx primarily serves patients with severe autoimmune diseases through prescriptions written by specialist physicians. Its medicines are used by neurologists, rheumatologists, and other specialty clinicians in treatment settings where biologic therapy is appropriate. - **Autoimmune disease patients** (primary) — Patients treated for conditions such as myasthenia gravis and other immune-mediated disorders. - **Specialist physicians** (primary) — Neurologists, rheumatologists, and other specialists prescribing VYVGART-family products. - **Hospitals and treatment centers** (secondary) — Sites that administer infused or subcutaneous specialty therapies and manage care pathways. - **Payers and PBMs** (primary) — They determine access, reimbursement, and formulary placement for branded biologics. - **Clinical trial investigators** (secondary) — Academic and specialty centers participating in argenx-sponsored studies and development programs. - Patients with severe autoimmune disease - Specialist physicians prescribing biologic therapy - Hospitals and infusion/treatment centers - Payers and pharmacy benefit managers - Healthcare systems using specialty medicines ## Geography argenx is headquartered in Amsterdam and operates as a global company with listings in Europe and the United States. Its commercial and development footprint is international, reflecting the need to run clinical trials, regulatory filings, and specialty medicine launches across major healthcare markets. - **Europe** (40%) — Headquartered in the Netherlands and listed on Euronext Brussels - **North America** (45%) — Major commercial and investor market including Nasdaq listing - **Rest of World** (15%) — Other international markets and clinical development geographies - Headquartered in Amsterdam, the Netherlands - Listed on Euronext Brussels and Nasdaq - Commercial reach spans North America, Europe, and other markets - Clinical development is multi-country and global - Specialty medicine operations depend on local regulatory access ## Strategy argenx is focused on broadening the clinical use of its FcRn-blocking medicines while advancing additional antibody-based programs in immunology. It also prioritizes building a global commercial organization and expanding the label, reach, and durability of its core therapy franchise. - **Expand approved immunology franchise** (medium-term) — Broader indications increase the addressable market and support durable commercial growth. - **Advance FcRn platform into new diseases** (medium-term) — The same mechanism can be studied across multiple autoimmune conditions. - **Strengthen global commercialization** (short-term) — Specialty biologics require specialist education, payer access, and coordinated market entry. - Expand use of VYVGART across additional autoimmune indications - Advance earlier-stage antibody programs in immunology - Grow global commercial infrastructure for specialty launches - Broaden physician adoption and payer access - Use academic partnerships to feed discovery and translational work ## Risks argenx depends on successful clinical development, regulatory approvals, and sustained physician adoption of specialty biologics. As a global immunology company, it also faces competition, reimbursement pressure, safety monitoring obligations, and execution risk in launching and expanding complex therapies. - **Clinical development failure** [high] — Pipeline value depends on positive trial data in multiple autoimmune indications. - **Regulatory and label risk** [high] — Approvals, label scope, and post-marketing requirements shape commercial potential. - **Reimbursement and access pressure** [high] — Specialty biologics require payer coverage and favorable formulary positioning. - **Safety and pharmacovigilance risk** [medium] — Immunology medicines can carry infection and other adverse-event concerns. - **Competition in autoimmune therapies** [medium] — Other biologics and emerging mechanisms can compete for the same patients. - Clinical trials may fail to show efficacy or safety - Regulatory approvals can be delayed or restricted - Payer access and reimbursement can limit uptake - Safety warnings can affect prescribing and use - Competition in autoimmune biologics may intensify ## Accounting argenx reports under IFRS and uses judgment-heavy accounting for intangible assets, deferred tax assets, and share-based compensation. For a biopharma company, the timing of development costs, capitalization of intangibles, and fair-value measurements can materially affect reported earnings and asset values. - **R&D expense recognition** — Can cause large swings in period results - **Deferred tax assets** — Could affect balance sheet valuation - **Intangible asset amortization** — Affects operating profit and net income - **Share-based compensation** — Raises operating expense and dilutes EPS - **Fair value measurements** — Can create volatility in other income - R&D expense timing affects operating results and comparability - Deferred tax assets depend on future taxable profits - Intangible asset amortization affects reported earnings - Share-based compensation is a meaningful non-cash expense - Fair value changes can affect financial income and equity --- *Last updated: 2026-09-28T11:57:32.230540+00:00*